Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print June 15, 2005, doi:10.1212/01.WNL.0000167129.90918.f5)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.WNL.0000167129.90918.f5v1
65/1/153    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Soilu-Hänninen, M.
Right arrow Articles by Waris, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soilu-Hänninen, M.
Right arrow Articles by Waris, M.
Received February 15, 2005
Accepted April 6, 2005

High sensitivity measurement of CRP and disease progression in multiple sclerosis

M. Soilu-Hänninen MD, PhD*, J. O. Koskinen MSc, M. Laaksonen MD, A. Hänninen MD, PhD, E.-M. Lilius PhD, and M. Waris PhD

From the Departments of Neurology (Dr. Soilu-Hänninen), Virology (Dr. Laaksonen), Biochemistry (Dr. Lilius), and Medical Microbiology (Dr. Hänninen), and the Laboratory of Biophysics (Dr. Koskinen), Institute of Biomedicine, University of Turku, Finland.


* To whom correspondence should be addressed. E-mail: mersoi{at}utu.fi.

Abstract-- The authors measured serum C-reactive protein (CRP) serially in patients with multiple sclerosis (MS) who participated the PRISMS study using a high-sensitivity technique. CRP values were similar in patients with MS and in healthy controls but higher during MS relapses than in remission (p = 0.010). CRP levels were lower during treatment with high-dose interferon beta 1a than placebo (p = 0.035) and higher during first 12 months of study in patients who progressed by year 4 compared with stable patients (p = 0.007).




This article has been cited by other articles:


Home page
 Mult SclerHome page
J Sellner, I Greeve, and H. Mattle
Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis
Multiple Sclerosis, August 1, 2008; 14(7): 981 - 984.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by AAN Enterprises, Inc.